LeadArtis participates in the second IACT update meeting as well as in the “Immunostimulatory monoclonal antibodies and immunomodulation: harvesting the crop“ international symposium


The second IACT assessment meeting took place during November 20-21, 2015 in Pamplona, Spain. LeadArtis is a partner of the Immunostimulatory Agonist Antibodies for Cancer Therapy, a 6.9M€ funding consortium which incorporates long-standing expertise in agonist immunostimulatory antibodies (IS-Abs) from research institutions and small-medium enterprises (SEM) in five European countries (Germany, Italy, Spain, Sweden and United Kingdom). The IACT program aims to translate the agonist IS-Ab concept into clinical treatments (http://www.iact-project.eu/). Two ongoing clinical trials are pivotal to bring forward the pre-clinical Proof of Concept. An analogous SME-driven effort aims at the development of 2nd generation agonist IS-Abs with superior therapeutic index. In this regard, LeadArtis will apply its TrimerbodyTM technology. The meeting focused on the progress and key capacities.

Additionally, LeadArtis participated in the “Immunostimulatory monoclonal antibodies and immunomodulation: harvesting the crop” International Symposium (Pamplona 18th-20th, 2015) where numerous worldwide renowned immune-oncology clinical and academic researchers presented and discussed their most recent contributions to the field. The meeting was organized by the Fundación para la Investigación Médica Aplicada – FIMA, Clínica Universidad de Navarra-CUN and Fundación Ramón Arece

Latest News

LeadArtis participates in the fourth Immunostimulatory Agonist Antibodies for Cancer Therapy (IACT) meeting in London (UK)

The fourth IACT review meeting took place on October 25-26, 2017 in London, United Kingdom....

LeadArtis discloses ATTACK, a novel bispecific T cell-recruiting antibody approach for cancer immunotherapy

LeadArtis´scientists, in collaboration with other prime...

Leadartis successfully accomplishes the TERET project

Leadartis is proud to announce the successful conclusion of the TERET (New Treatments for...